Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review
M Guirado, E Fernández Martín… - Clinical and …, 2022 - Springer
Introduction Due to the importance of lung cancer early treatment because of its severity and
extent worldwide a systematic literature review was conducted about the impact of delays in …
extent worldwide a systematic literature review was conducted about the impact of delays in …
Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals
M Cavic, A Krivokuca, I Boljevic, J Spasic… - Expert review of …, 2021 - Taylor & Francis
ABSTRACT Background: The SARS-CoV-2 pandemic introduced a global distraction effect
in cancer patients' care. The aim of this study was to explore the effect of the pandemic on …
in cancer patients' care. The aim of this study was to explore the effect of the pandemic on …
European Respiratory Society guideline on various aspects of quality in lung cancer care
This European Respiratory Society guideline is dedicated to the provision of good quality
recommendations in lung cancer care. All the clinical recommendations contained were …
recommendations in lung cancer care. All the clinical recommendations contained were …
[HTML][HTML] Real-world ALK testing trends in patients with advanced non–small-cell lung cancer in the United States
HM Lin, Y Wu, Y Yin, H Niu, EA Curran, CM Lovly… - Clinical Lung Cancer, 2023 - Elsevier
Introduction Patients with non–small-cell lung cancer (NSCLC) whose tumors harbor
anaplastic lymphoma kinase (ALK) rearrangements can be treated with ALK tyrosine kinase …
anaplastic lymphoma kinase (ALK) rearrangements can be treated with ALK tyrosine kinase …
Inequalities in survival and care across social determinants of health in a cohort of advanced lung cancer patients in Quebec (Canada): A high‐resolution population …
S Qureshi, G Boily, J Boulanger, É Pagé… - Cancer …, 2023 - Wiley Online Library
Background Advanced lung cancer patients exposed to breakthrough therapies like EGFR
tyrosine kinase inhibitors (EGFR‐TKI) may experience social inequalities in survival, partly …
tyrosine kinase inhibitors (EGFR‐TKI) may experience social inequalities in survival, partly …
Impact of co-pay assistance on patient, clinical, and economic outcomes.
OBJECTIVES: Patient assistance programs (eg, co-pay assistance) may reduce patients' out-
of-pocket costs for prescription medicines, providing financial assistance to access …
of-pocket costs for prescription medicines, providing financial assistance to access …
[HTML][HTML] Assessing the impact of limited distribution drug networks based on time to accessing oral oncolytic agents at an integrated specialty pharmacy
M Jagasia - 2020 - jhoponline.com
BACKGROUND: Barriers to accessing oral oncolytic therapy include insurance prior
authorization, high copays, and limited distribution drug networks. These barriers increase …
authorization, high copays, and limited distribution drug networks. These barriers increase …
Access to tyrosine kinase inhibitors and survival in patients with advanced EGFR+ and ALK+ positive non–small-cell lung Cancer treated in the real-world
BHL Goulart, S Chennupati, CR Fedorenko… - Clinical Lung Cancer, 2021 - Elsevier
Introduction We assessed the proportion of patients with advanced epidermal growth factor
receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive non–small-cell lung cancer …
receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive non–small-cell lung cancer …
Referred molecular testing as a barrier to optimal treatment decision making in metastatic non‐small cell lung cancer: Experience at a tertiary academic institution in …
GK Grafham, KJ Craddock, WY Huang… - Cancer …, 2024 - Wiley Online Library
Background Molecular testing is critical to guiding treatment approaches in patients with
metastatic non‐small cell lung cancer (mNSCLC), with testing delays adversely impacting …
metastatic non‐small cell lung cancer (mNSCLC), with testing delays adversely impacting …
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for …
CM Bestvina, D Waters, L Morrison… - Journal of Medical …, 2024 - Taylor & Francis
Aims To assess US payers' per-patient cost of testing associated with next-generation
sequencing (NGS) versus polymerase chain reaction (PCR) biomarker testing strategies …
sequencing (NGS) versus polymerase chain reaction (PCR) biomarker testing strategies …